Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?

被引：0
|
作者：
Pier Paolo M. Berton Giachetti
Giuseppe Curigliano
机构：
[1] Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS),Division of Early Drug Development for Innovative Therapy, European Institute of Oncology
[2] University of Milan,Department of Oncology and Hemato
来源：
Nature Reviews Clinical Oncology | 2024年 / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Recent results from the phase III PHILA trial demonstrate a benefit in terms of progression-free survival derived from the addition of pyrotinib to first-line chemotherapy plus trastuzumab in patients with metastatic HER2-positive breast cancer. Dual HER2 blockade with pyrotinib and trastuzumab is an effective therapeutic strategy but might increase the risk of gastrointestinal toxicity; therefore, the risk-to-benefit ratio should be carefully evaluated.
引用
收藏
页码：171 / 172
页数：1
相关论文
共 50 条
  • [31] Interim safety of pertuzumab in combination with trastuzumab and vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer
    Perez, E.
    Lopez-Vega, J. M.
    Petit, T.
    Zamagni, C.
    Freudensprung, U.
    Bastiere-Truchot, L.
    Walker, R.
    Andersson, M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S178 - S179
  • [32] PertuzumabIn the First-Line Treatment of HER2-Positive Metastatic Breast Cancer
    Gillian M. Keating
    Drugs, 2012, 72 : 353 - 360
  • [33] Pertuzumab In the First-Line Treatment of HER2-Positive Metastatic Breast Cancer
    Keating, Gillian M.
    DRUGS, 2012, 72 (03) : 353 - 360
  • [34] AVEREL: a randomized Phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer
    不详
    BREAST CANCER MANAGEMENT, 2013, 2 (04) : 274 - 274
  • [35] AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
    Gianni, Luca
    Romieu, Gilles H.
    Lichinitser, Michail
    Serrano, Sergio V.
    Mansutti, Mauro
    Pivot, Xavier
    Mariani, Paola
    Andre, Fabrice
    Chan, Arlene
    Lipatov, Oleg
    Chan, Stephen
    Wardley, Andrew
    Greil, Richard
    Moore, Nicola
    Prot, Sylvie
    Pallaud, Celine
    Semiglazov, Vladimir
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (14) : 1719 - +
  • [36] PI3K Pathway Activity and Response to First-Line Chemotherapy in Combination with Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer
    Vorkas, P. A.
    Agelaki, S.
    Poumpouridou, N.
    Kroupis, C.
    Mavroudis, D.
    Stathopoulos, E.
    Georgoulias, V
    Liandou, E. S.
    CANCER RESEARCH, 2009, 69 (24) : 599S - 599S
  • [37] Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis
    You, Shuhui
    Xie, Yizhao
    Sang, Die
    Luo, Ting
    Yuan, Peng
    Xu, Fei
    Wang, Biyun
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [38] HER2-positive metastatic Breast Cancer Trastuzumab Emtansine: First Choice for the Second Line
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (11) : 744 - 744
  • [39] Oral vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced HER2-positive breast cancer
    Ghosn, M.
    Kattan, J.
    Chahine, G.
    Makdessi, J.
    Bitar, N.
    El-Mouhebb, M.
    Mourad, C.
    Farhat, F.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S182 - S183
  • [40] ORAL VINORELBINE IN COMBINATION WITH TRASTUZUMAB AS A FIRST LINE THERAPY OF METASTATIC OR LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER
    Farhat, Fadi
    Kattan, Joseph
    Ghosn, Marwan
    BREAST, 2015, 24 : S42 - S43
12345